Abstract
Gliomatosis cerebri (GC) is defined as a glioma that intensely infiltrates the brain with expansion in at least three cerebral lobes. In the current version of the WHO classification of brain tumors GC is listed among astrocytic tumors due to morphological similarities. Because of the malignant course of the disease the WHO assigned an anaplastic grade (WHO grade III) to this tumor entity. Due to the various settings in which the definition criteria of GC are fulfilled it was suggested to divide GC in primary and secondary GC. Furthermore, the definition of primary GC (pGC) contains subgroups classified by diffuse growth without (type I, the ‘classical’ variant) or with a solid tumor portion (type II). A diffuse infiltration initiating from a solid tumor is classified as secondary GC (sGC). Various studies analysed genetic alterations in GC that typically occur in diffusely infiltrating gliomas. Some findings suggested genetically a relation between GC and low-grade astrocytomas. However, the frequency of identified genetic glioma-like alterations in GC was rather low. Recently, mutations in the IDH1 gene were identified in a high frequency nearly only in diffusely infiltrating gliomas of the WHO grades II and III and in secondary glioblastomas. The marker was successfully used to separate these tumors from other entities that may show morphologically similarities. Therefore, IDH1 mutations seem to be a promising marker to determine the relationship of GC to diffusely infiltrating gliomas. Interestingly, IDH1 mutations were identified only in pGC type II, but not in ‘classical’ pGC type I. These findings support the notion that the current definition of GC allows inclusion of different tumor entities and indicates that ‘classical’ pGC type I is rather not that related to diffusely infiltrating gliomas as formerly assumed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Artigas J, Cervos-Navarro J, Iglesias JR, Ebhardt G (1985) Gliomatosis cerebri: clinical and histological findings. Clin Neuropathol 4:135–148
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 6:597–602
Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 5:599–601
Cervos-Navarro J, Artigas J, Aruffo C, Iglesias J (1987) The fine structure of gliomatosis cerebri. Virchows Arch A Pathol Anat Histopathol 1:93–98
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 7274:739–744
Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 21:1792–1795
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 4:469–474
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 6:707–718
Herrlinger U, Felsberg J, Kuker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M (2002) Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol 4:390–399
Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75(17):1560–1566
Jennings MT, Frenchman M, Shehab T, Johnson MD, Creasy J, LaPorte K, Dettbarn WD (1995) Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 1:37–45
Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
Kleihues P, Burger PC, Scheithauer BW, Zülch KJ (1993) Histological typing of tumours of the central nervous system. Springer, Berlin/Heidelberg/New York
Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 3:401–405
Kros JM, Zheng P, Dinjens WN, Alers JC (2002) Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis. J Neuropathol Exp Neurol 9:806–814
Louis DN, International Agency for Research on Cancer (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon
Mawrin C (2005) Molecular genetic alterations in gliomatosis cerebri: what can we learn about the origin and course of the disease? Acta Neuropathol 6:527–536
Mawrin C, Kirches E, Schneider-Stock R, Scherlach C, Vorwerk C, Von Deimling A, Van Landeghem F, Meyermann R, Bornemann A, Muller A, Romeike B, Stoltenburg-Didinger G, Wickboldt J, Pilz P, Dietzmann K (2003) Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol 6:529–536
Mawrin C, Kirches E, Schneider-Stock R, Boltze C, Vorwerk CK, von Mawrin A, von Deimling A, Stoltenburg-Didinge G, Bornemann A, Romeike B, Sellhaus B, Dietzmann K (2005) Alterations of cell cycle regulators in gliomatosis cerebri. J Neurooncol 2:115–122
Nevin S (1938) Gliomatosis cerebri. Brain 61:170–191
Park S, Suh YL, Nam DH, Kim ST (2009) Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 2:73–82
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 5897:1807–1812
Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH (2003) Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys 4:1137–1146
Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY (2004) Initial chemotherapy in gliomatosis cerebri. Neurology 2:270–275
Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 25:4150–4154
Schober R, Mai JK, Volk B, Wechsler W (1991) Gliomatosis cerebri: bioptical approach and neuropathological verification. Acta Neurochir (Wien) 3–4:131–137
Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C (2010) Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 2:261–267
Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, Sanson M (2006) Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 2:201–205
Vates GE, Chang S, Lamborn KR, Prados M, Berger MS (2003) Gliomatosis cerebri: a review of 22 cases. Neurosurgery 2:261–271, discussion 271
Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network. J Clin Oncol 34:5743–5750
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 35:5874–5880
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 1:17–30
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 8:765–773
Zülch KJ, World Health Organization (1979) Histological typing of tumours of the central nervous system. World Health Organization, Geneva
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Seiz, M., Hartmann, C. (2014). Gliomatosis Cerebri: Implications of Genetic Findings. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 11. Tumors of the Central Nervous System, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7037-9_7
Download citation
DOI: https://doi.org/10.1007/978-94-007-7037-9_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7036-2
Online ISBN: 978-94-007-7037-9
eBook Packages: MedicineMedicine (R0)